Engineered cardiac tissue model of restrictive cardiomyopathy for drug discovery
Wang B, Nash T, Zhang X, Rao J, Abriola L, Kim Y, Zakharov S, Kim M, Luo L, Morsink M, Liu B, Lock R, Fleischer S, Tamargo M, Bohnen M, Welch C, Chung W, Marx S, Surovtseva Y, Vunjak-Novakovic G, Fine B. Engineered cardiac tissue model of restrictive cardiomyopathy for drug discovery. Cell Reports Medicine 2023, 4: 100976. PMID: 36921598, PMCID: PMC10040415, DOI: 10.1016/j.xcrm.2023.100976.Peer-Reviewed Original ResearchMeSH KeywordsCardiomyopathy, RestrictiveDrug DiscoveryHumansMyocardiumMyocytes, CardiacTissue EngineeringConceptsRestrictive cardiomyopathyElevated ventricular filling pressuresVentricular filling pressurePrecision medicine approachVariety of cardiomyopathiesPluripotent stem cell-derived cardiomyocytesStem cell-derived cardiomyocytesDiastolic relaxationCardiomyocyte relaxationFilamin CMyocardial relaxationCell-derived cardiomyocytesFilling pressurePotential therapyRelaxation velocityMyocardial stiffnessCalcium kineticsMedicine approachCardiomyopathyTranslational potentialIsogenic control linesCardiac tissuePassive tensionScreening identifiesTissue model